David Shackleford

Dr David Shackleford

Dr David Shackleford

Section Leader, Biopharmaceutics
Centre for Drug Candidate Optimisation (CDCO)
Tel: +61 3 990 39065
Email: david.shackleford@monash.edu
ROPES
LinkdIn
CDCO Website

Biography:

David Shackleford leads the Biopharmaceutics section of the Centre for Drug Candidate Optimisation (CDCO). He completed his studies at the University of South Australia before moving to Melbourne to undertake a post-doctoral position with Professor Christopher Porter and Professor Susan Charman in the  Department of Pharmaceutics, Monash University. David specialises in pharmacokinetics and drug metabolism within the area of ADME lead optimisation. In 2003, he joined the CDCO as the Metabolism Team Leader, and in 2004 this role was expanded to that of Biopharmaceutics Section Leader, focusing on both  the in vitro and in vivo classification of PK/ADME properties for novel drug candidates. Outside of work he enjoys various interests including racing bicycles, flying gliders, building model aircraft and swing dancing.

Publications

Leong, N., Prankerd, R.J., Shackleford, D., McIntosh, M.P., 2015, Evaluation of the impact of sulfobutylether7-beta-cyclodextrin on the liquid chromatography-mass spectrometry analysis of biological samples arising from in vivo pharmacokinetic studies, Journal of Pharmaceutical Sciences [P], vol 104, issue 4, John Wiley & Sons Inc., Hoboken NJ USA, pp. 1561-1562.

Landersdorfer, C.B., Caliph, S.M., Shackleford, D., Ascher, D.B., Kaminskas, L.M., 2015, PEGylated interferon displays differences in plasma clearance and bioavailability between male and female mice and between female immunocompetent C57Bl/6J and athymic nude mice, Journal of Pharmaceutical Sciences [P], vol 104, issue 5, John Wiley & Sons Inc., Hoboken NJ USA, pp. 1848-1855.

Leong, N., Prankerd, R.J., Shackleford, D., McIntosh, M.P., 2015, The effect of intravenous sulfobutylether7-?-cyclodextrin on the pharmacokinetics of a series of adamantane-containing compounds, Journal of Pharmaceutical Sciences [P], vol 104, issue 4, John Wiley & Sons Inc., Hoboken NJ USA, pp. 1492-1498.

Jimenez-Diaz, M., Ebert, D., Salinas, Y., Pradhan, A., Lehane, A.M., Myrand-Lapierre, M., O'Loughlin, K.G., Shackleford, D., Justino de Almeida, M., Carrillo, A., Clark, J.A., Dennis, A.S.M., Diep, J., Deng, X., Duffy, S., Endsley, A.N., Fedewa, G., Guiguemde, W.A., Gomez, M.G., Holbrook, G., Horst,  J.A., Kim, C.C., Liu, J., Lee, M.C.S., Matheny, A., Martinez, M.S., Miller, G.E., Rodriguez-Alejandre, A., Sanz, L.M., Sigal, M., Spillman, N.J., Stein, P.D., Wang, Z., Zhu, F., Waterson, D., Knapp, S., Shelat, A.A., Avery, V.M., Fidock, D.A., Gamo, F., Charman, S.A., Mirsalis, J.C., Ma, H., Ferrer,  S.B., Kirk, K., Angulo-Barturen, I., Kyle, D.E., de Risi, J.L., Floyd, D.M., Guy, R.K., 2014, (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium,Proceedings Of The National Academy Of Sciences Of The United States Of America [P], vol 111, issue 50, National Academy of Sciences, Washington DC USA, pp. e5455-e5462.

Bahia, M.T., Nascimento, A.F.S., Mazzeti, A.L., Marques, L.F., Goncalves, K.R., Mota, L.W.R., Diniz, L.d.F., Caldas, I.S., Talvani, A., Shackleford, D., Koltun, M., Saunders, J., White, K.L., Scandale, I., Charman, S.A., Chatelain, E., 2014, Antitrypanosomal activity of fexinidazole metabolites, potential  new drug candidates for Chagas disease, Antimicrobial Agents And Chemotherapy [P], vol 58, issue 8, American Society for Microbiology, Washington DC USA, pp. 4362-4370.

Dr David Shackleford

Dr David Shackleford

Section Leader, Biopharmaceutics
Centre for Drug Candidate Optimisation (CDCO)
Tel: +61 3 990 39065
Email: david.shackleford@monash.edu
ROPES
LinkdIn
CDCO Website

Biography:

David Shackleford leads the Biopharmaceutics section of the Centre for Drug Candidate Optimisation (CDCO). He completed his studies at the University of South Australia before moving to Melbourne to undertake a post-doctoral position with Professor Christopher Porter and Professor Susan Charman in the Department of Pharmaceutics, Monash University. David specialises in pharmacokinetics and drug metabolism within the area of ADME lead optimisation. In 2003, he joined the CDCO as the Metabolism Team Leader, and in 2004 this role was expanded to that of Biopharmaceutics Section Leader, focusing on both the in vitro and in vivo classification of PK/ADME properties for novel drug candidates. Outside of work he enjoys various interests including racing bicycles, flying gliders, building model aircraft and swing dancing.

Publications

Leong, N., Prankerd, R.J., Shackleford, D., McIntosh, M.P., 2015, Evaluation of the impact of sulfobutylether7-beta-cyclodextrin on the liquid chromatography-mass spectrometry analysis of biological samples arising from in vivo pharmacokinetic studies, Journal of Pharmaceutical Sciences [P], vol 104, issue 4, John Wiley & Sons Inc., Hoboken NJ USA, pp. 1561-1562.

Landersdorfer, C.B., Caliph, S.M., Shackleford, D., Ascher, D.B., Kaminskas, L.M., 2015, PEGylated interferon displays differences in plasma clearance and bioavailability between male and female mice and between female immunocompetent C57Bl/6J and athymic nude mice, Journal of Pharmaceutical Sciences [P], vol 104, issue 5, John Wiley & Sons Inc., Hoboken NJ USA, pp. 1848-1855.

Leong, N., Prankerd, R.J., Shackleford, D., McIntosh, M.P., 2015, The effect of intravenous sulfobutylether7-?-cyclodextrin on the pharmacokinetics of a series of adamantane-containing compounds, Journal of Pharmaceutical Sciences [P], vol 104, issue 4, John Wiley & Sons Inc., Hoboken NJ USA, pp. 1492-1498.

Jimenez-Diaz, M., Ebert, D., Salinas, Y., Pradhan, A., Lehane, A.M., Myrand-Lapierre, M., O'Loughlin, K.G., Shackleford, D., Justino de Almeida, M., Carrillo, A., Clark, J.A., Dennis, A.S.M., Diep, J., Deng, X., Duffy, S., Endsley, A.N., Fedewa, G., Guiguemde, W.A., Gomez, M.G., Holbrook, G., Horst, J.A., Kim, C.C., Liu, J., Lee, M.C.S., Matheny, A., Martinez, M.S., Miller, G.E., Rodriguez-Alejandre, A., Sanz, L.M., Sigal, M., Spillman, N.J., Stein, P.D., Wang, Z., Zhu, F., Waterson, D., Knapp, S., Shelat, A.A., Avery, V.M., Fidock, D.A., Gamo, F., Charman, S.A., Mirsalis, J.C., Ma, H., Ferrer, S.B., Kirk, K., Angulo-Barturen, I., Kyle, D.E., de Risi, J.L., Floyd, D.M., Guy, R.K., 2014, (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium,Proceedings Of The National Academy Of Sciences Of The United States Of America [P], vol 111, issue 50, National Academy of Sciences, Washington DC USA, pp. e5455-e5462.

Bahia, M.T., Nascimento, A.F.S., Mazzeti, A.L., Marques, L.F., Goncalves, K.R., Mota, L.W.R., Diniz, L.d.F., Caldas, I.S., Talvani, A., Shackleford, D., Koltun, M., Saunders, J., White, K.L., Scandale, I., Charman, S.A., Chatelain, E., 2014, Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease, Antimicrobial Agents And Chemotherapy [P], vol 58, issue 8, American Society for Microbiology, Washington DC USA, pp. 4362-4370.